Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARG1 Peptide Vaccine in Metastatic Solid Tumors
NCT03689192Phase 1Completed
- Sponsor
- Herlev Hospital
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of arginase-1 peptide vaccine in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), Malignant Melanoma (MM) and 5 more, sponsored by Herlev Hospital. Primary endpoint: Adverse Events. Started Dec 2018; status: completed.
02
Drugs
arginase-1 peptide vaccine
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)Malignant Melanoma (MM)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03689192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689192.